Brown Capital Management LLC lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 11.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,195,319 shares of the company's stock after selling 288,386 shares during the quarter. Brown Capital Management LLC owned 1.81% of 10x Genomics worth $49,570,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in TXG. Allspring Global Investments Holdings LLC increased its stake in 10x Genomics by 113.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company's stock valued at $26,000 after purchasing an additional 371 shares during the last quarter. Covestor Ltd grew its position in shares of 10x Genomics by 501.7% in the 1st quarter. Covestor Ltd now owns 1,047 shares of the company's stock valued at $39,000 after buying an additional 873 shares during the last quarter. GAMMA Investing LLC raised its stake in 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after acquiring an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in 10x Genomics in the third quarter valued at $35,000. Finally, Blue Trust Inc. boosted its stake in 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock valued at $40,000 after acquiring an additional 1,025 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on TXG shares. Canaccord Genuity Group reduced their target price on shares of 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, October 10th. JPMorgan Chase & Co. decreased their price objective on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a research report on Wednesday, October 30th. Leerink Partners assumed coverage on 10x Genomics in a report on Tuesday, September 3rd. They issued an "outperform" rating and a $35.00 target price on the stock. Leerink Partnrs raised 10x Genomics to a "strong-buy" rating in a report on Tuesday, September 3rd. Finally, UBS Group dropped their price objective on shares of 10x Genomics from $25.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, 10x Genomics presently has a consensus rating of "Moderate Buy" and an average target price of $29.19.
Get Our Latest Report on TXG
10x Genomics Trading Up 0.5 %
Shares of NASDAQ TXG traded up $0.06 on Thursday, reaching $13.38. 1,048,254 shares of the company traded hands, compared to its average volume of 1,727,764. The stock has a market capitalization of $1.62 billion, a PE ratio of -8.75 and a beta of 1.87. 10x Genomics, Inc. has a fifty-two week low of $12.95 and a fifty-two week high of $57.90. The company has a 50 day moving average of $17.73 and a 200 day moving average of $20.06.
10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company had revenue of $151.65 million during the quarter, compared to analysts' expectations of $158.84 million. During the same period in the previous year, the company earned ($0.51) EPS. The business's quarterly revenue was down 1.3% compared to the same quarter last year. As a group, research analysts expect that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.
About 10x Genomics
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Articles
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
